We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
206 result(s) found, displaying 41 to 50
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 4 TAKEDA, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack.
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIVTENCITY maribavir 200 mg film coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 30 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 10 mg film-coated tablet bottle.
-
Australian public assessment report (AusPar)AusPAR for Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies
-
Prescription medicine registrationActive ingredients: vedolizumab.
-
Australian public assessment report (AusPar)AusPAR for Exkivity (Mobocertinib) for treatment of patients with locally advanced or metastatic non-small lung cancer.
-
Designation or determinationOrphan drug